[go: up one dir, main page]

PE20110121A1 - Composiciones farmaceuticas de aliskiren - Google Patents

Composiciones farmaceuticas de aliskiren

Info

Publication number
PE20110121A1
PE20110121A1 PE2010000272A PE2010000272A PE20110121A1 PE 20110121 A1 PE20110121 A1 PE 20110121A1 PE 2010000272 A PE2010000272 A PE 2010000272A PE 2010000272 A PE2010000272 A PE 2010000272A PE 20110121 A1 PE20110121 A1 PE 20110121A1
Authority
PE
Peru
Prior art keywords
aliskiren
cross
cellulose
stearate
linked
Prior art date
Application number
PE2010000272A
Other languages
English (en)
Inventor
Petra Gisela Rigassi-Dietrich
Martin Schimd
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34994415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110121(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20110121A1 publication Critical patent/PE20110121A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMA SOLIDA DE DOSIFICACION ORAL QUE COMPRENDE: A) ALISKIREN O UNA SAL FARMACEUTICAMENTE ACEPTABLE EN UNA CANTIDAD MAYOR A 46% EN PESO BASADO EN PESO TOTAL; B) RELLENO SELECCIONADO DE UNO O MAS DE CELULOSA MICROCRISTALINA, ALMIDON DE PAPA, ALMIDON DE TRIGO, HIDROXIPROPILCELULOSA, AZUCAR DE CONFITERIA, DEXTRINA; C) UN AGLUTINANTE SELECCIONADO DE UNO O MAS DE POLIVINILPIRROLIDONAS, POLIETILENGLICOLES Y HPMC; D) DESINTEGRANTE SELECCIONADO DE UNO O MAS POLIVINILPIRROLIDONA ENTRECRUZADA, CARBOXIMETILCELULOSA ENTRECRUZADA, ACIDO ALGINICO, GOMA GUAR Y CARBOXIMETILCELULOSA; E) DESLIZANTE SELECCIONADO DE UNO O MAS SILICA COLOIDAL, DIOXIDO DE SILICIO COLOIDAL, CELULOSA EN POLVO, ENTRE OTROS; F) LUBRICANTE SELECCIONADO DE UNO O MAS DE ESTEARATO DE MAGNESIO, ESTEARTO DE ALUMINIO, ESTEARATO DE CALCIO, ACEITE DE CASTOR HIDROGENADO, ENTRE OTROS. DICHA FORMA FARMACEUTICA. DICHA FORMULACION PERMITE LA FORMULACION ROBUSTA DE ALISKIREN UTIL EN EL TRATAMIENTO DE HIPERTENSION O FALLA CARDIACA CONGESTIVA
PE2010000272A 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren PE20110121A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55387804P 2004-03-17 2004-03-17

Publications (1)

Publication Number Publication Date
PE20110121A1 true PE20110121A1 (es) 2011-02-28

Family

ID=34994415

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2005000288A PE20060075A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de alisciren
PE2010000272A PE20110121A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren
PE2014001265A PE20142101A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2005000288A PE20060075A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de alisciren

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014001265A PE20142101A1 (es) 2004-03-17 2005-03-15 Composiciones farmaceuticas de aliskiren

Country Status (24)

Country Link
US (3) US8617595B2 (es)
EP (2) EP2283826B1 (es)
JP (2) JP2007529456A (es)
KR (2) KR101274855B1 (es)
CN (2) CN1997354B (es)
AR (1) AR048431A1 (es)
AU (2) AU2005224010B2 (es)
BR (1) BRPI0508833A (es)
CA (1) CA2554633C (es)
EC (1) ECSP066807A (es)
ES (1) ES2747941T3 (es)
IL (1) IL177424A0 (es)
MA (1) MA28490B1 (es)
MX (1) MX347617B (es)
MY (2) MY148773A (es)
NO (1) NO343217B1 (es)
NZ (1) NZ548823A (es)
PE (3) PE20060075A1 (es)
RU (3) RU2384328C2 (es)
SG (1) SG153830A1 (es)
TN (1) TNSN06294A1 (es)
TW (1) TWI406656B (es)
WO (1) WO2005089729A2 (es)
ZA (1) ZA200606220B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60331849D1 (de) * 2002-11-05 2010-05-06 Glaxosmithkline Llc Antibakterielle wirkstoffe
US20070191487A1 (en) * 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic compounds
CA2645260A1 (en) * 2006-04-03 2007-10-18 Novartis Ag Renin inhibitors for the treatment of hypertension
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
JP2010508370A (ja) * 2006-11-07 2010-03-18 ノバルティス アーゲー ヘミフマル酸アリスキレンの結晶形
JP2010509254A (ja) * 2006-11-09 2010-03-25 ノバルティス アーゲー アリスキレンとオロチン酸の塩
JP2010518147A (ja) * 2007-02-16 2010-05-27 ノバルティス アーゲー 有機化合物の使用
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
US20090082458A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched aliskiren
EP2548553A1 (en) * 2007-09-28 2013-01-23 Novartis AG Galenical formulations of aliskiren
BRPI0817275A2 (pt) * 2007-09-28 2015-06-16 Novartis Ag Combinação farmacêutica de alisquireno e valsartana
WO2009045795A2 (en) * 2007-09-28 2009-04-09 Novartis Ag Galenical formulations of aliskiren and valsartan
US20120029083A1 (en) 2007-11-13 2012-02-02 Teva Pharmaceutical Industries, Ltd. Polymorphic forms of aliskiren hemifumarate and process for preparation thereof
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
CA2724320A1 (en) * 2008-06-06 2009-12-10 Teva Pharmaceutical Industries Ltd. Solid states of aliskiren free base
EP2143425A1 (de) 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
US20100093603A1 (en) * 2008-07-17 2010-04-15 Kenneth Baker Use of organic compounds
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
US9026212B2 (en) 2008-09-23 2015-05-05 Incube Labs, Llc Energy harvesting mechanism for medical devices
AR073651A1 (es) * 2008-09-24 2010-11-24 Novartis Ag Formulaciones galenicas de compuestos organicos
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
WO2010086312A1 (en) 2009-01-28 2010-08-05 Novartis Ag Galenic formulations of organic compounds
EP2340820A1 (en) 2009-12-16 2011-07-06 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EP2216020A1 (en) 2009-02-05 2010-08-11 KRKA, tovarna zdravil, d.d., Novo mesto Moisture-activated granulation process
EA201190091A1 (ru) 2009-02-05 2012-01-30 Крка, Товарна Здравил, Д. Д., Ново Место Активируемый влагой способ грануляции
BRPI1009131A2 (pt) * 2009-03-20 2016-03-01 Novartis Ag composição farmacêutica compreendendo aliscireno
RU2011142081A (ru) 2009-03-20 2013-04-27 Новартис Аг Галеновые фиксированные комбинации валсартана и алискирена
JP2010280601A (ja) * 2009-06-04 2010-12-16 Suntory Holdings Ltd キシロオリゴ糖高含有錠剤
WO2011028919A2 (en) 2009-09-03 2011-03-10 Teva Pharmaceutical Industries Ltd. Solid forms of aliskiren hemifumarate and processes for preparation thereof
EP2382967A1 (de) 2010-04-21 2011-11-02 ratiopharm GmbH Aliskiren in Form einer festen Dispersion
US20110268797A1 (en) 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations
US20130129791A1 (en) * 2010-05-04 2013-05-23 Mahmut Bilgic Preparations of effervescent formulations comprising second and third generation cephalosporin and uses thereof
JP2015537029A (ja) 2012-11-14 2015-12-24 ダブリュー・アール・グレース・アンド・カンパニー−コーンＷ Ｒ Ｇｒａｃｅ ＆ Ｃｏ−Ｃｏｎｎ 生物学的に活性な物質及び不規則性無機酸化物を含有する組成物
CN103099793B (zh) * 2013-02-06 2015-07-15 中国人民解放军第二军医大学 片剂及其制备方法
CN103536576B (zh) * 2013-10-15 2015-07-01 海南卫康制药(潜山)有限公司 阿利吉仑组合物胶囊
RU2545833C1 (ru) * 2013-12-03 2015-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПХФА Минздрава России) Фармацевтическая композиция с антиишемической и антиоксидантной активностью и способ ее получения
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
EP4085902B1 (en) * 2019-12-31 2025-04-30 Jiangsu Yahong Meditech Co., Ltd. Pharmaceutical composition containing nitroxoline, nitroxoline tablet, preparation method therefor and use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3039922A (en) * 1959-08-17 1962-06-19 Carter Prod Inc Method of administering tablets having decongestant and anti-histaminic activity
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
DE19820801A1 (de) * 1998-05-09 1999-11-25 Gruenenthal Gmbh Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
DE60039802D1 (de) * 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
US6264983B1 (en) * 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
EP1312379A4 (en) 2000-08-25 2004-08-25 Takeda Chemical Industries Ltd FIBRINOGENING AGENTS
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
EP1250921A1 (en) * 2001-04-21 2002-10-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Fast disintegrating meloxicam tablet
JP2003015880A (ja) * 2001-06-29 2003-01-17 Toshiba Corp 携帯情報端末およびアドインプログラム起動方法
AU2002363087A1 (en) * 2001-10-18 2003-05-06 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
DK1507558T3 (da) * 2002-05-17 2011-12-05 Novartis Pharma Ag Farmaceutisk sammensætning omfattende en renininhibitor, en calciumkanalblokker og et diuretikum
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings

Also Published As

Publication number Publication date
MY148773A (en) 2013-05-31
NO20064670L (no) 2006-10-16
AU2009202069B2 (en) 2012-02-16
SG153830A1 (en) 2009-07-29
TWI406656B (zh) 2013-09-01
ES2747941T3 (es) 2020-03-12
TW200534843A (en) 2005-11-01
US8007824B2 (en) 2011-08-30
US20050272790A1 (en) 2005-12-08
US20060018960A1 (en) 2006-01-26
AU2005224010A1 (en) 2005-09-29
US20070197655A1 (en) 2007-08-23
EP2283826A2 (en) 2011-02-16
KR101274855B1 (ko) 2013-06-13
PE20142101A1 (es) 2014-12-27
WO2005089729A2 (en) 2005-09-29
EP1729736A2 (en) 2006-12-13
RU2384328C2 (ru) 2010-03-20
US7683054B2 (en) 2010-03-23
PE20060075A1 (es) 2006-03-20
CA2554633C (en) 2014-07-08
MY144477A (en) 2011-09-30
RU2438661C2 (ru) 2012-01-10
CA2554633A1 (en) 2006-09-29
JP2012211152A (ja) 2012-11-01
CN1997354B (zh) 2013-09-11
RU2480210C1 (ru) 2013-04-27
US8617595B2 (en) 2013-12-31
RU2006136090A (ru) 2008-04-27
CN103462913A (zh) 2013-12-25
NO343217B1 (no) 2018-12-03
AR048431A1 (es) 2006-04-26
KR20070006776A (ko) 2007-01-11
NZ548823A (en) 2011-02-25
BRPI0508833A (pt) 2007-08-14
EP2283826B1 (en) 2019-09-04
RU2011135405A (ru) 2013-03-10
AU2009202069A1 (en) 2009-06-18
WO2005089729A3 (en) 2006-10-12
JP5925607B2 (ja) 2016-05-25
CN1997354A (zh) 2007-07-11
KR20130028803A (ko) 2013-03-19
MX347617B (es) 2017-05-04
TNSN06294A1 (en) 2007-12-03
AU2005224010B2 (en) 2009-02-26
RU2009138446A (ru) 2011-04-27
KR101353736B1 (ko) 2014-01-22
EP2283826A3 (en) 2013-08-07
JP2007529456A (ja) 2007-10-25
MA28490B1 (fr) 2007-03-01
ECSP066807A (es) 2006-11-16
ZA200606220B (en) 2008-04-30
IL177424A0 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
PE20110121A1 (es) Composiciones farmaceuticas de aliskiren
MY157790A (en) Trazodone composition for once a day administration
WO2007048219A3 (en) Sustained drug release composition
MX343358B (es) Tabletas de acetato de ulipristal.
EP2493312A4 (en) Solid pharmaceutical compositions containing an integrase inhibitor
TW200621317A (en) Pharmaceutical composition
EP1750862A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING IRBESARTAN
WO2009087633A3 (en) Methods and compositions for oral administration of protein and peptide therapeutic agents
MX2010001839A (es) Metodo y aparato para comunicacion y metodo y aparato para controlar comunicacion.
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
MEP55308A (en) New pharmaceutical compositions containing flibanserin polymorph a
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
WO2007100382A3 (en) Orally administrable gallium compositions and method of use
HRP20100120T1 (hr) Formulacije s valsartanom
PE20120990A1 (es) Formulaciones de alisquireno e hidroclorotiazida
EP3978027A4 (en) PHYSIOLOGICALLY ACTIVE SUBSTANCE LINKED TO A BIOTIN FRACTION, AND COMPOSITION FOR ORAL ADMINISTRATION COMPRISING IT
EA201001108A1 (ru) Диспергируемые во рту таблетки, содержащие основание эсциталопрама, и способ их получения
WO2020101597A3 (en) Capsule compositions comprising tyrosine-kinase inhibitors
WO2008012474A3 (fr) Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees
CL2020000124A1 (es) Composiciones sólidas orales de betahistina de liberación prolongada no pulsátil.
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
UA92463C2 (ru) Производные пиримидинсульфонамида как модуляторы рецепторов хемокина
WO2020032883A3 (en) Synergistic effects of a novel ketoprofen formulation including a gastro protective agent

Legal Events

Date Code Title Description
FC Refusal